AstraZeneca's new pill, elecoglipron, is showing promising results in the crowded race to bring weight-loss medications to patients who prefer tablets over injections. The British pharmaceutical company announced phase 2 trial results this week indicating that the oral drug produces weight loss comparable to other GLP-1 pills already on the market—a significant milestone as the appetite-suppressing drug category explodes in popularity.
The trial, which involved 310 overweight or obese adults without diabetes, showed that participants taking the highest dose of elecoglipron achieved average weight reductions of 10.5% at 26 weeks and 11.8% at 36 weeks, according to results published in the Lancet medical journal. These figures place the Cambridge-based company firmly in contention with competitors Novo Nordisk and Eli Lilly, whose injectable GLP-1 agonists have become bestsellers globally, transforming how millions of people approach weight management.
The side effect profile was reassuring: nausea remained the most common adverse effect, mirroring what researchers have observed with other oral GLP-1 drugs. This consistency suggests elecoglipron could become a viable alternative in a treatment landscape that has exploded over the past few years. The massive popularity of GLP-1 injectables has sparked a pharmaceutical arms race to develop easier-to-use tablet versions that don't require needles or regular clinic visits.
However, experts caution that these phase 2 results, while encouraging, represent only an early step toward regulatory approval. Marie Spreckley, a weight management researcher at the University of Cambridge who was not involved in the study, emphasized that larger and longer phase 3 trials will be essential to confirm whether the effects last, establish longer-term safety and tolerability, and determine where elecoglipron fits among the expanding arsenal of obesity and diabetes treatments.
The competitive landscape is already crowded. Eli Lilly received U.S. approval in April for the oral form of its blockbuster drug Mounjaro, sold under the brand name Foundayo. Novo Nordisk's pill version of Wegovy is already available in the United States, and European Union health authorities gave it the green light last month. Both companies have major market advantages with established reputations, manufacturing infrastructure, and patients already familiar with their injectable versions.
Yet opportunity remains substantial. The global appetite for effective weight-loss medications has only intensified, with shortages of injectable GLP-1 drugs continuing in many regions. A convenient pill form could expand access and appeal to patients who hesitate at needles or struggle with injection logistics. AstraZeneca's entry into this market, pending successful phase 3 trials, could reshape an already dynamic sector.
The next phase of development will be crucial. Spreckley's call for more rigorous, longer-term trials reflects the standard caution of the scientific community—but also hints at genuine optimism about elecoglipron's potential. If the drug proves durable and well-tolerated over months or years, it could offer patients yet another effective option in a class of medications that has fundamentally changed approaches to weight management.